Quest Diagnostics has enjoyed a powerful multi year run, and the question now is whether the current share price is still grounded in the cash the business can generate. With the spotlight back on reimbursement policy and regulation, the stock's valuation is increasingly tied to how durable those cash flows prove to be.
- Over the past 3 years the share price has gained 103.7%, which puts real pressure on the idea that earnings and free cash flow can keep carrying that kind of advance.
- As the company pushes for the RESULTS Act to reshape Medicare and Medicaid lab payment rules, future reimbursement terms may support or restrain the cash flow that underpins any valuation based on its testing franchise.
- If you'd rather focus on earnings, this one's for you. See why Quest Diagnostics's 25.4x P/E tells a different valuation story.
The issue now is whether Quest Diagnostics' current market price is adequately supported by the cash flows implied by its intrinsic value under a Discounted Cash Flow (DCF) approach.
If you are comparing Quest Diagnostics with other opportunities that are also evaluated on valuation and quality, it can be helpful to consider it alongside 32 high quality undervalued stocks.
Does Quest Diagnostics Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model here uses a 2 Stage Free Cash Flow to Equity approach built on Quest Diagnostics' ability to keep generating cash from its lab network. Latest twelve month free cash flow sits at about $1.42b in $ terms, and the projections assume this testing business can support gradually expanding annual cash flows rather than sharp swings.
Looking out across the next decade, the DCF path points to free cash flow projections in the low to mid single digit growth range, which is consistent with a mature operator rather than a high risk early stage story. That stream of expected cash is what puts the estimated intrinsic value substantially above the current share price of $259.65, even after allowing for discounting and a second stage that cools the growth rate. Because looming Medicare and Medicaid lab payment cuts are in focus through the RESULTS Act debate, the reimbursement overhang helps explain why the market price still trails what this discounted cash flow profile implies. Find out what Quest Diagnostics could be worth using our Discounted Cash Flow (DCF) estimate.
The Quest Diagnostics Narrative: What Would Justify Today's Price?
Narratives pick up where that valuation puzzle leaves off for Quest Diagnostics, by spelling out which future paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. They sit on Simply Wall St’s Community page as ongoing reference points. Each one treats fair value as a hypothesis about how the business develops over time, so you can watch how that story holds up as new information arrives.
One of the top narratives on Quest Diagnostics: roughly fairly valued
This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.
"The main factor that has to go right is that Quest Diagnostics continues to scale automation, AI tools, and lab productivity programs so that cost savings and service quality keep pace..."
Discover why this Narrative puts Quest Diagnostics at roughly fairly valued.
Quest Diagnostics: why the people running it still need a closer look
Cash flows and share price only tell part of the story, because who steers Quest Diagnostics and how those leaders are rewarded can heavily influence long term outcomes for shareholders. See who runs Quest Diagnostics and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com